Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer
Abstract
:1. Introduction
2. Circulating miRNAs as Indicators of Clinical Response to NAT in BC
3. Discussion
4. Conclusions
5. Future Directions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
Breast cancer | BC |
Neoadjuvant therapy | NAT |
microRNAs | miRNAs |
Pathologic complete response | pCR |
Triple-negative BC | TNBC |
3′-untranslated region | 3′-UTR |
High-density lipoproteins | HDL |
Trichorhinophalangeal syndrome type 1 protein | TRPS1 |
Epithelial-to-mesenchymal transition | EMT |
Multidrug resistance protein 1 | MRP-1 |
Estrogen receptor 1 | ESR1 |
Circulating tumor cells | CTCs |
Progesterone receptor | PGR |
Estrogen receptor | ER |
Event-free survival | EFS |
BC stem cell | BCSC |
neoadjuvant polychemotherapy | NPCT |
Mitofusin-2 | MFN2 |
Adriamycin | ADR |
Clinical complete response | cCR |
Protein inhibitor of activated signal transducer and activator of transcription 4 | PIAS4 |
Miller–Payne | MP |
Programmed cell death 4 | PDCD4 |
Invasive ductal carcinoma | IDC |
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Pashayan, N.; Antoniou, A.C.; Ivanus, U.; Esserman, L.J.; Easton, D.F.; French, D.; Sroczynski, G.; Hall, P.; Cuzick, J.; Evans, D.G.; et al. Personalized Early Detection and Prevention of Breast Cancer: ENVISION Consensus Statement. Nat. Rev. Clin. Oncol. 2020, 17, 687–705. [Google Scholar] [CrossRef]
- Waks, A.G.; Winer, E.P. Breast Cancer Treatment. Am. Fam. Physician 2021, 104, 171–178. [Google Scholar] [CrossRef]
- Selli, C.; Sims, A.H. Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research. Breast Cancer Basic Clin. Res. 2019, 13, 1178223419829072. [Google Scholar] [CrossRef] [Green Version]
- Tilsed, C.M.; Fisher, S.A.; Nowak, A.K.; Lake, R.A.; Lesterhuis, W.J. Cancer Chemotherapy: Insights into Cellular and Tumor Microenvironmental Mechanisms of Action. Front. Oncol. 2022, 12, 960317. [Google Scholar] [CrossRef] [PubMed]
- Masoud, V.; Pagès, G. Targeted Therapies in Breast Cancer: New Challenges to Fight against Resistance. World J. Clin. Oncol. 2017, 8, 120–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Johnston, S.J.; Cheung, K.-L. Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. Oncol. Ther. 2018, 6, 141–156. [Google Scholar] [CrossRef] [Green Version]
- Asaoka, M.; Gandhi, S.; Ishikawa, T.; Takabe, K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer Basic Clin. Res. 2020, 14, 1178223420980377. [Google Scholar] [CrossRef]
- Korde, L.A.; Somerfield, M.R.; Carey, L.A.; Crews, J.R.; Denduluri, N.; Shelley Hwang, E.; Khan, S.A.; Loibl, S.; Morris, E.A.; Perez, A.; et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J. Clin. Oncol. 2021, 39, 1485–1505. [Google Scholar] [CrossRef]
- Rizzo, A.; Cusmai, A.; Massafra, R.; Bove, S.; Comes, M.; Fanizzi, A.; Rinaldi, L.; Acquafredda, S.; Gadaleta-Caldarola, G.; Oreste, D.; et al. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Cells 2022, 11, 1857. [Google Scholar] [CrossRef]
- Spring, L.M.; Fell, G.; Arfe, A.; Sharma, C.; Greenup, R.; Reynolds, K.L.; Smith, B.L.; Alexander, B.; Moy, B.; Isakoff, S.J.; et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-Analysis. Clin. Cancer Res. 2020, 26, 2838–2848. [Google Scholar] [CrossRef]
- Wang-Lopez, Q.; Chalabi, N.; Abrial, C.; Radosevic-Robin, N.; Durando, X.; Mouret-Reynier, M.-A.; Benmammar, K.-E.; Kullab, S.; Bahadoor, M.; Chollet, P.; et al. Can Pathologic Complete Response (PCR) Be Used as a Surrogate Marker of Survival after Neoadjuvant Therapy for Breast Cancer? Crit. Rev. Oncol. Hematol. 2015, 95, 88–104. [Google Scholar] [CrossRef] [PubMed]
- Torrisi, R.; Marrazzo, E.; Agostinetto, E.; De Sanctis, R.; Losurdo, A.; Masci, G.; Tinterri, C.; Santoro, A. Neoadjuvant Chemotherapy in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: When, Why and What? Crit. Rev. Oncol. Hematol. 2021, 160, 103280. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Zhang, H.; Li, C.; Xiang, Q.; Xu, L.; Liu, Q.; Pang, X.; Zhang, W.; Zhang, H.; Zhang, S.; et al. Circulating MicroRNAs as Indicators in the Prediction of Neoadjuvant Chemotherapy Response in Luminal B Breast Cancer. Thorac. Cancer 2021, 12, 3396–3406. [Google Scholar] [CrossRef]
- Asselain, B.; Barlow, W.; Bartlett, J.; Bergh, J.; Bergsten-Nordström, E.; Bliss, J.; Boccardo, F.; Boddington, C.; Bogaerts, J.; Bonadonna, G.; et al. Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy in Early Breast Cancer: Meta-Analysis of Individual Patient Data from Ten Randomised Trials. Lancet Oncol. 2018, 19, 27–39. [Google Scholar] [CrossRef] [Green Version]
- Derouane, F.; van Marcke, C.; Berlière, M.; Gerday, A.; Fellah, L.; Leconte, I.; Van Bockstal, M.R.; Galant, C.; Corbet, C.; Duhoux, F.P. Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. Cancers 2022, 14, 3876. [Google Scholar] [CrossRef]
- de Freitas, A.J.A.; Causin, R.L.; Varuzza, M.B.; Hidalgo Filho, C.M.T.; da Silva, V.D.; Souza, C.d.P.; Marques, M.M.C. Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review. Cancers 2021, 13, 5477. [Google Scholar] [CrossRef] [PubMed]
- Iwamoto, T.; Kajiwara, Y.; Zhu, Y.; Iha, S. Biomarkers of Neoadjuvant/Adjuvant Chemotherapy for Breast Cancer. Chin. Clin. Oncol. 2020, 9, 27. [Google Scholar] [CrossRef]
- Bownes, R.; Turnbull, A.; Cameron, D.; Sims, A.; Oikonomidou, O. On-Treatment Biomarkers Can Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Res. 2019, 79, P3-11-13. [Google Scholar] [CrossRef]
- Asaoka, M.; Narui, K.; Suganuma, N.; Chishima, T.; Yamada, A.; Sugae, S.; Kawai, S.; Uenaka, N.; Teraoka, S.; Miyahara, K.; et al. Clinical and Pathological Predictors of Recurrence in Breast Cancer Patients Achieving Pathological Complete Response to Neoadjuvant Chemotherapy. Eur. J. Surg. Oncol. 2019, 45, 2289–2294. [Google Scholar] [CrossRef]
- Wu, H.J.; Chu, P.Y. Current and Developing Liquid Biopsy Techniques for Breast Cancer. Cancers 2022, 14, 2052. [Google Scholar] [CrossRef]
- Cirmena, G.; Dameri, M.; Ravera, F.; Fregatti, P.; Ballestrero, A.; Zoppoli, G. Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications. Cancers 2021, 13, 3460. [Google Scholar] [CrossRef] [PubMed]
- Rahat, B.; Ali, T.; Sapehia, D.; Mahajan, A.; Kaur, J. Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine. Front. Genet. 2020, 11, 844. [Google Scholar] [CrossRef] [PubMed]
- Tierno, D.; Grassi, G.; Zanconati, F.; Bortul, M.; Scaggiante, B. An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2023, 24, 1799. [Google Scholar] [CrossRef] [PubMed]
- Cardinali, B.; Tasso, R.; Piccioli, P.; Ciferri, M.C.; Quarto, R.; Del Mastro, L. Circulating MiRNAs in Breast Cancer Diagnosis and Prognosis. Cancers 2022, 14, 2317. [Google Scholar] [CrossRef] [PubMed]
- Treiber, T.; Treiber, N.; Meister, G. Regulation of MicroRNA Biogenesis and Its Crosstalk with Other Cellular Pathways. Nat. Rev. Mol. Cell Biol. 2019, 20, 5–20. [Google Scholar] [CrossRef]
- Benavides-Aguilar, J.A.; Morales-Rodríguez, J.I.; Ambriz-González, H.; Ruiz-Manriquez, L.M.; Banerjee, A.; Pathak, S.; Duttaroy, A.K.; Paul, S. The Regulatory Role of MicroRNAs in Common Eye Diseases: A Brief Review. Front. Genet. 2023, 14, 1152110. [Google Scholar] [CrossRef]
- Brümmer, A.; Hausser, J. MicroRNA Binding Sites in the Coding Region of MRNAs: Extending the Repertoire of Post-Transcriptional Gene Regulation. BioEssays 2014, 36, 617–626. [Google Scholar] [CrossRef]
- Dexheimer, P.J.; Cochella, L. MicroRNAs: From Mechanism to Organism. Front. Cell Dev. Biol. 2020, 8, 409. [Google Scholar] [CrossRef]
- Shu, J.; Silva, B.V.R.e.; Gao, T.; Xu, Z.; Cui, J. Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers. Sci. Rep. 2017, 7, 13356. [Google Scholar] [CrossRef] [Green Version]
- Ledesma-Pacheco, S.J.; Uriostegui-Pena, A.G.; Rodriguez-Jacinto, E.; Gomez-Hernandez, E.; Estrada-Meza, C.; Banerjee, A.; Pathak, S.; Ruiz-Manriquez, L.M.; Duttaroy, A.K.; Paul, S. Regulatory Mechanisms of MicroRNAs in Endocrine Disorders and Their Therapeutic Potential. Front. Genet. 2023, 14, 1137017. [Google Scholar] [CrossRef]
- He, B.; Zhao, Z.; Cai, Q.; Zhang, Y.; Zhang, P.; Shi, S.; Xie, H.; Peng, X.; Yin, W.; Tao, Y.; et al. Mirna-Based Biomarkers, Therapies, and Resistance in Cancer. Int. J. Biol. Sci. 2020, 16, 2628–2647. [Google Scholar] [CrossRef]
- Bravo-Vázquez, L.A.; Frías-Reid, N.; Ramos-Delgado, A.G.; Osorio-Pérez, S.M.; Zlotnik-Chávez, H.R.; Pathak, S.; Banerjee, A.; Bandyopadhyay, A.; Duttaroy, A.K.; Paul, S. MicroRNAs and Long Non-Coding RNAs in Pancreatic Cancer: From Epigenetics to Potential Clinical Applications. Transl. Oncol. 2023, 27, 101579. [Google Scholar] [CrossRef]
- Ruiz-Manriquez, L.M.; Carrasco-Morales, O.; Sanchez, Z.E.A.; Osorio-Perez, S.M.; Estrada-Meza, C.; Pathak, S.; Banerjee, A.; Bandyopadhyay, A.; Duttaroy, A.K.; Paul, S. MicroRNA-Mediated Regulation of Key Signaling Pathways in Hepatocellular Carcinoma: A Mechanistic Insight. Front. Genet. 2022, 13, 910733. [Google Scholar] [CrossRef] [PubMed]
- Ebrahimi, S.O.; Reiisi, S.; Shareef, S. MiRNAs, Oxidative Stress, and Cancer: A Comprehensive and Updated Review. J. Cell. Physiol. 2020, 235, 8812–8825. [Google Scholar] [CrossRef] [PubMed]
- Sengupta, D.; Deb, M.; Kar, S.; Pradhan, N.; Parbin, S.; Kirtana, R.; Singh, S.P.; Suma, S.; Niharika; Roy, A.; et al. Dissecting MiRNA Facilitated Physiology and Function in Human Breast Cancer for Therapeutic Intervention. Semin. Cancer Biol. 2021, 72, 46–64. [Google Scholar] [CrossRef] [PubMed]
- Shaw, P.; Lokhotiya, K.; Kumarasamy, C.; Sunil, K.; Suresh, D.; Shetty, S.; Muthukaliannan, G.K.; Baxi, S.; Mani, R.R.; Sivanandy, P.; et al. Mapping Research on MiRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis. Pathophysiology 2022, 29, 66–80. [Google Scholar] [CrossRef] [PubMed]
- Smolarz, B.; Durczyński, A.; Romanowicz, H.; Szyłło, K.; Hogendorf, P. MiRNAs in Cancer (Review of Literature). Int. J. Mol. Sci. 2022, 23, 2805. [Google Scholar] [CrossRef]
- Hamam, R.; Hamam, D.; Alsaleh, K.A.; Kassem, M.; Zaher, W.; Alfayez, M.; Aldahmash, A.; Alajez, N.M. Circulating MicroRNAs in Breast Cancer: Novel Diagnostic and Prognostic Biomarkers. Cell Death Dis. 2017, 8, e3045. [Google Scholar] [CrossRef] [Green Version]
- El-Daly, S.M.; Gouhar, S.A.; Elmageed, Z.Y.A. Circulating MicroRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application. J. Pharmacol. Exp. Ther. 2023, 384, 35–51. [Google Scholar] [CrossRef]
- Lin, S.; Gregory, R.I. MicroRNA Biogenesis Pathways in Cancer. Nat. Rev. Cancer 2015, 15, 321–333. [Google Scholar] [CrossRef] [PubMed]
- Condrat, C.E.; Thompson, D.C.; Barbu, M.G.; Bugnar, O.L.; Boboc, A.; Cretoiu, D.; Suciu, N.; Cretoiu, S.M.; Voinea, S.C. MiRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells 2020, 9, 276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Winkle, M.; El-Daly, S.M.; Fabbri, M.; Calin, G.A. Noncoding RNA Therapeutics—Challenges and Potential Solutions. Nat. Rev. Drug Discov. 2021, 20, 629–651. [Google Scholar] [CrossRef] [PubMed]
- Cui, M.; Wang, H.; Yao, X.; Zhang, D.; Xie, Y.; Cui, R.; Zhang, X. Circulating MicroRNAs in Cancer: Potential and Challenge. Front. Genet. 2019, 10, 626. [Google Scholar] [CrossRef] [Green Version]
- Filipów, S.; Łaczmański, Ł. Blood Circulating MiRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response. Front. Neurosci. 2019, 13, 169. [Google Scholar] [CrossRef]
- Wang, H.; Peng, R.; Wang, J.; Qin, Z.; Xue, L. Circulating MicroRNAs as Potential Cancer Biomarkers: The Advantage and Disadvantage. Clin. Epigenet. 2018, 10, 59. [Google Scholar] [CrossRef] [Green Version]
- Tan, S.; Xia, L.; Yi, P.; Han, Y.; Tang, L.; Pan, Q.; Tian, Y.; Rao, S.; Oyang, L.; Liang, J.; et al. Exosomal MiRNAs in Tumor Microenvironment. J. Exp. Clin. Cancer Res. 2020, 39, 67. [Google Scholar] [CrossRef]
- Xu, R.; Rai, A.; Chen, M.; Suwakulsiri, W.; Greening, D.W.; Simpson, R.J. Extracellular Vesicles in Cancer—Implications for Future Improvements in Cancer Care. Nat. Rev. Clin. Oncol. 2018, 15, 617–638. [Google Scholar] [CrossRef]
- Li, I.; Nabet, B.Y. Exosomes in the Tumor Microenvironment as Mediators of Cancer Therapy Resistance. Mol. Cancer 2019, 18, 32. [Google Scholar] [CrossRef]
- Patel, H.; Nilendu, P.; Jahagirdar, D.; Pal, J.K.; Sharma, N.K. Modulating Secreted Components of Tumor Microenvironment: A Masterstroke in Tumor Therapeutics. Cancer Biol. Ther. 2018, 19, 3–12. [Google Scholar] [CrossRef]
- Annese, T.; Tamma, R.; De Giorgis, M.; Ribatti, D. MicroRNAs Biogenesis, Functions and Role in Tumor Angiogenesis. Front. Oncol. 2020, 10, 581007. [Google Scholar] [CrossRef]
- Zhu, W.; Liu, M.; Fan, Y.; Ma, F.; Xu, N.; Xu, B. Dynamics of Circulating MicroRNAs as a Novel Indicator of Clinical Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Med. 2018, 7, 4420–4433. [Google Scholar] [CrossRef] [Green Version]
- Stevic, I.; Müller, V.; Weber, K.; Fasching, P.A.; Karn, T.; Marmé, F.; Schem, C.; Stickeler, E.; Denkert, C.; Van Mackelenbergh, M.; et al. Specific MicroRNA Signatures in Exosomes of Triple-Negative and HER2-Positive Breast Cancer Patients Undergoing Neoadjuvant Therapy within the GeparSixto Trial. BMC Med. 2018, 16, 179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akkiprik, M.; Koca, S.; Uğurlu, M.; Ekren, R.; Eyüboğlu, I.P.; Alan, Ö.; Erzik, C.; Amuran, G.G.; Telli, T.A.; Güllüoğlu, M.B.; et al. Response Assessment with Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients with Locally Advanced Breast Cancer during Neoadjuvant Chemotherapy. Clin. Breast Cancer 2020, 20, 332–343.e3. [Google Scholar] [CrossRef]
- Di Cosimo, S.; Appierto, V.; Pizzamiglio, S.; Silvestri, M.; Baselga, J.; Piccart, M.; Huober, J.; Izquierdo, M.; de la Pena, L.; Hilbers, F.S.; et al. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. Int. J. Mol. Sci. 2020, 21, 1386. [Google Scholar] [CrossRef] [Green Version]
- Di Cosimo, S.; Appierto, V.; Pizzamiglio, S.; Tiberio, P.; Iorio, M.V.; Hilbers, F.; De Azambuja, E.; De La Peña, L.; Izquierdo, M.; Huober, J.; et al. Plasma MiRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer: Results from the NeoALTTO Trial. Clin. Cancer Res. 2019, 25, 3887–3895. [Google Scholar] [CrossRef] [Green Version]
- Baldasici, O.; Balacescu, L.; Cruceriu, D.; Roman, A.; Lisencu, C.; Fetica, B.; Visan, S.; Cismaru, A.; Jurj, A.; Barbu-Tudoran, L.; et al. Circulating Small EVs MiRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients. Int. J. Mol. Sci. 2022, 23, 2625. [Google Scholar] [CrossRef] [PubMed]
- Liu, B.; Su, F.; Lv, X.; Zhang, W.; Shang, X.; Zhang, Y.; Zhang, J. Serum MicroRNA-21 Predicted Treatment Outcome and Survival in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Combined with Trastuzumab. Cancer Chemother. Pharmacol. 2019, 84, 1039–1049. [Google Scholar] [CrossRef] [PubMed]
- Sukhija, S.; Purohit, P.; Pareek, P.; Garg, P.K.; Vishnoi, J.R.; Elhence, P.A.; Varthya, S.B.; Sharma, P.; Ambwani, S.; Charan, J. Circulating MiRNA-21 Levels in Breast Cancer Patients Before and After Chemotherapy and Its Association with Clinical Improvement. Indian J. Clin. Biochem. 2023. [Google Scholar] [CrossRef]
- McGuire, A.; Casey, M.C.; Waldron, R.M.; Heneghan, H.; Kalinina, O.; Holian, E.; McDermott, A.; Lowery, A.J.; Newell, J.; Dwyer, R.M.; et al. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers 2020, 12, 1820. [Google Scholar] [CrossRef]
- Ibrahim, A.M.; Said, M.M.; Hilal, A.M.; Medhat, A.M.; Abd Elsalam, I.M. Candidate Circulating MicroRNAs as Potential Diagnostic and Predictive Biomarkers for the Monitoring of Locally Advanced Breast Cancer Patients. Tumour. Biol. 2020, 42, 1010428320963811. [Google Scholar] [CrossRef]
- Rodríguez-Martínez, A.; De Miguel-Pérez, D.; Ortega, F.G.; García-Puche, J.L.; Robles-Fernández, I.; Exposito, J.; Martorell-Marugan, J.; Carmona-Sáez, P.; Garrido-Navas, M.D.C.; Rolfo, C.; et al. Exosomal MiRNA Profile as Complementary Tool in the Diagnostic and Prediction of Treatment Response in Localized Breast Cancer under Neoadjuvant Chemotherapy. Breast Cancer Res. 2019, 21, 21. [Google Scholar] [CrossRef] [PubMed]
- Todorova, V.K.; Byrum, S.D.; Gies, A.J.; Haynie, C.; Smith, H.; Reyna, N.S.; Makhoul, I. Circulating Exosomal MicroRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer. Curr. Oncol. 2022, 29, 613–630. [Google Scholar] [CrossRef]
- Chekhun, V.F.; Borikun, T.V.; Bazas, V.; Andriiv, A.V.; Klyusov, O.; Yalovenko, T.; Lukianova, N.Y. Association of Circulating MiR-21, -205, and -182 with Response of Luminal Breast Cancers to Neoadjuvant FAC and AC Treatment. Exp. Oncol. 2020, 42, 162–166. [Google Scholar] [CrossRef]
- Ritter, A.; Hirschfeld, M.; Berner, K.; Rücker, G.; Jäger, M.; Weiss, D.; Medl, M.; Nöthling, C.; Gassner, S.; Asberger, J.; et al. Circulating Non-Coding RNA-Biomarker Potential in Neoadjuvant Chemotherapy of Triple Negative Breast Cancer? Int. J. Oncol. 2020, 56, 47–68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davey, M.G.; Casey, M.C.; McGuire, A.; Waldron, R.M.; Paganga, M.; Holian, E.; Newell, J.; Heneghan, H.M.; McDermott, A.M.; Keane, M.M.; et al. Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer: A Prospective, Multicenter Clinical Trial. Ann. Surg. 2022, 276, 905. [Google Scholar] [CrossRef]
- Liang, Y.K.; Lin, H.Y.; Dou, X.W.; Chen, M.; Wei, X.L.; Zhang, Y.Q.; Wu, Y.; Chen, C.F.; Bai, J.W.; Xiao, Y.S.; et al. MiR-221/222 Promote Epithelial-Mesenchymal Transition by Targeting Notch3 in Breast Cancer Cell Lines. NPJ Breast Cancer 2018, 4, 20. [Google Scholar] [CrossRef] [Green Version]
- Stinson, S.; Lackner, M.R.; Adai, A.T.; Yu, N.; Kim, H.-J.; O’Brien, C.; Spoerke, J.; Jhunjhunwala, S.; Boyd, Z.; Januario, T.; et al. TRPS1 Targeting by MiR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer. Sci. Signal 2011, 4, ra41. [Google Scholar] [CrossRef] [PubMed]
- Emran, T.B.; Shahriar, A.; Mahmud, A.R.; Rahman, T.; Abir, M.H.; Siddiquee, M.F.R.; Ahmed, H.; Rahman, N.; Nainu, F.; Wahyudin, E.; et al. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front. Oncol. 2022, 12, 891652. [Google Scholar] [CrossRef]
- Zhu, H.; Wu, H.; Liu, X.; Evans, B.R.; Medina, D.J.; Liu, C.-G.; Yang, J.-M. Role of MicroRNA MiR-27a and MiR-451 in the Regulation of MDR1/P-Glycoprotein Expression in Human Cancer Cells. Biochem. Pharmacol. 2008, 76, 582–588. [Google Scholar] [CrossRef] [Green Version]
- Luengo-Gil, G.; Gonzalez-Billalabeitia, E.; Perez-Henarejos, S.A.; Navarro Manzano, E.; Chaves-Benito, A.; Garcia-Martinez, E.; Garcia-Garre, E.; Vicente, V.; De La Peña, F.A. Angiogenic Role of MiR-20a in Breast Cancer. PLoS ONE 2018, 13, e0194638. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, K.; Chadalapaka, G.; Lee, S.-O.; Yamada, D.; Sastre-Garau, X.; Defossez, P.-A.; Park, Y.-Y.; Lee, J.-S.; Safe, S. Identification of Oncogenic MicroRNA-17-92/ZBTB4/Specificity Protein Axis in Breast Cancer. Oncogene 2012, 31, 1034–1044. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Imani, S.; Wu, R.C.; Fu, J. MicroRNA-34 Family in Breast Cancer: From Research to Therapeutic Potential. J. Cancer 2018, 9, 3765–3775. [Google Scholar] [CrossRef] [Green Version]
- von Minckwitz, G.; Loibl, S.; Untch, M.; Eidtmann, H.; Rezai, M.; Fasching, P.A.; Tesch, H.; Eggemann, H.; Schrader, I.; Kittel, K.; et al. Survival after Neoadjuvant Chemotherapy with or without Bevacizumab or Everolimus for HER2-Negative Primary Breast Cancer (GBG 44-GeparQuinto). Ann. Oncol. 2014, 25, 2363–2372. [Google Scholar] [CrossRef] [PubMed]
- von Minckwitz, G.; Schneeweiss, A.; Loibl, S.; Salat, C.; Denkert, C.; Rezai, M.; Blohmer, J.U.; Jackisch, C.; Paepke, S.; Gerber, B.; et al. Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. Lancet Oncol. 2014, 15, 747–756. [Google Scholar] [CrossRef] [PubMed]
- He, X.-H.; Zhu, W.; Yuan, P.; Jiang, S.; Li, D.; Zhang, H.-W.; Liu, M.-F. MiR-155 Downregulates ErbB2 and Suppresses ErbB2-Induced Malignant Transformation of Breast Epithelial Cells. Oncogene 2016, 35, 6015–6025. [Google Scholar] [CrossRef]
- Lettlova, S.; Brynychova, V.; Blecha, J.; Vrana, D.; Vondrusova, M.; Soucek, P.; Truksa, J. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer. Cell. Physiol. Biochem. 2018, 46, 2601–2615. [Google Scholar] [CrossRef] [PubMed]
- Ma, F.; Zhang, J.; Zhong, L.; Wang, L.; Liu, Y.; Wang, Y.; Peng, L.; Guo, B. Upregulated MicroRNA-301a in Breast Cancer Promotes Tumor Metastasis by Targeting PTEN and Activating Wnt/β-Catenin Signaling. Gene 2014, 535, 191–197. [Google Scholar] [CrossRef]
- Zhang, G.J.; Xiao, H.X.; Tian, H.P.; Liu, Z.L.; Xia, S.; Zhou, T. Upregulation of MicroRNA-155 Promotes the Migration and Invasion of Colorectal Cancer Cells through the Regulation of Claudin-1 Expression. Int. J. Mol. Med. 2013, 31, 1375–1380. [Google Scholar] [CrossRef] [Green Version]
- Ali, S.A.; Abdulrahman, Z.F.A.; Faraidun, H.N. Circulatory MiRNA-155, MiRNA-21 Target PTEN Expression and Activity as a Factor in Breast Cancer Development. Cell. Mol. Biol. 2020, 66, 44–50. [Google Scholar] [CrossRef]
- Jabbari, N.; Akbariazar, E.; Feqhhi, M.; Rahbarghazi, R.; Rezaie, J. Breast Cancer-Derived Exosomes: Tumor Progression and Therapeutic Agents. J. Cell. Physiol. 2020, 235, 6345–6356. [Google Scholar] [CrossRef]
- Qattan, A. Novel Mirna Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease. Int. J. Mol. Sci. 2020, 21, 8905. [Google Scholar] [CrossRef]
- Zhao, F.; Zhong, M.; Pei, W.; Tian, B.; Cai, Y. MiR-376c-3p Modulates the Properties of Breast Cancer Stem Cells by Targeting RAB2A. Exp. Ther. Med. 2020, 20, 68. [Google Scholar] [CrossRef]
- Li, H.; Li, Q.; He, S. Hsa_circ_0025202 Suppresses Cell Tumorigenesis and Tamoxifen Resistance via MiR-197-3p/HIPK3 Axis in Breast Cancer. World J. Surg. Oncol. 2021, 19, 39. [Google Scholar] [CrossRef] [PubMed]
- Luo, L.; Yang, R.; Zhao, S.; Chen, Y.; Hong, S.; Wang, K.; Wang, T.; Cheng, J.; Zhang, T.; Chen, D. Decreased MiR-320 Expression Is Associated with Breast Cancer Progression, Cell Migration, and Invasiveness via Targeting Aquaporin 1. Acta Biochim. Biophys. Sin. 2018, 50, 473–480. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Z.; Zhang, J.; Li, J.; Geng, H.; Zhou, B.; Zhang, B.; Chen, H. MiR-320/ELF3 Axis Inhibits the Progression of Breast Cancer via the PI3K/AKT Pathway. Oncol. Lett. 2020, 19, 3239–3248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fuso, P.; Di Salvatore, M.; Santonocito, C.; Guarino, D.; Autilio, C.; Mulè, A.; Arciuolo, D.; Rinninella, A.; Mignone, F.; Ramundo, M.; et al. Let-7a-5p, Mir-100-5p, Mir-101-3p, and Mir-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients. J. Pers. Med. 2021, 11, 816. [Google Scholar] [CrossRef]
- An, C.; Hu, Z.; Li, Y.; Zhao, P.; Liu, R.; Zhang, Q.; Zhu, P.; Li, Y.; Wang, Y. LINC00662 Enhances Cell Progression and Stemness in Breast Cancer by MiR-144-3p/SOX2 Axis. Cancer Cell Int. 2022, 22, 184. [Google Scholar] [CrossRef]
- Tang, W.; Zhang, X.; Tan, W.; Gao, J.; Pan, L.; Ye, X.; Chen, L.; Zheng, W. MiR-145-5p Suppresses Breast Cancer Progression by Inhibiting SOX2. J. Surg. Res. 2019, 236, 278–287. [Google Scholar] [CrossRef]
- Assiri, A.A.; Mourad, N.; Shao, M.; Kiel, P.; Liu, W.; Skaar, T.C.; Overholser, B.R. MicroRNA 362-3p Reduces HERG-Related Current and Inhibits Breast Cancer Cells Proliferation. Cancer Genom. Proteom. 2019, 16, 433–442. [Google Scholar] [CrossRef]
- Son, D.; Kim, Y.; Lim, S.; Kang, H.-G.; Kim, D.-H.; Park, J.W.; Cheong, W.; Kong, H.K.; Han, W.; Park, W.-Y.; et al. MiR-374a-5p Promotes Tumor Progression by Targeting ARRB1 in Triple Negative Breast Cancer. Cancer Lett. 2019, 454, 224–233. [Google Scholar] [CrossRef]
- Zha, Z.; Jia, F.; Hu, P.; Mai, E.; Lei, T. MicroRNA-574-3p Inhibits the Malignant Behavior of Liver Cancer Cells by Targeting ADAM28. Oncol. Lett. 2020, 20, 3015–3023. [Google Scholar] [CrossRef]
- Wu, D.; Zhang, J.; Lu, Y.; Bo, S.; Li, L.; Wang, L.; Zhang, Q.; Mao, J. MiR-140-5p Inhibits the Proliferation and Enhances the Efficacy of Doxorubicin to Breast Cancer Stem Cells by Targeting Wnt1. Cancer Gene Ther. 2019, 26, 74–82. [Google Scholar] [CrossRef]
- Deng, S.; Wang, M.; Wang, C.; Zeng, Y.; Qin, X.; Tan, Y.; Liang, B.; Cao, Y. P53 Downregulates PD-L1 Expression via MiR-34a to Inhibit the Growth of Triple-Negative Breast Cancer Cells: A Potential Clinical Immunotherapeutic Target. Mol. Biol. Rep. 2023, 50, 577–587. [Google Scholar] [CrossRef] [PubMed]
- Sun, D.; Luo, X.; Ma, L.; Wang, Y.; Zhang, F. Identifying of MiR-98-5p/IGF1 Axis Contributes Breast Cancer Progression Using Comprehensive Bioinformatic Analyses Methods and Experiments Validation. Life Sci. 2020, 261, 118435. [Google Scholar] [CrossRef]
- Ruiz-Manriquez, L.M.; Estrada-Meza, C.; Benavides-Aguilar, J.A.; Ledesma-Pacheco, S.J.; Torres-Copado, A.; Serrano-Cano, F.I.; Bandyopadhyay, A.; Pathak, S.; Chakraborty, S.; Srivastava, A.; et al. Phytochemicals Mediated Modulation of MicroRNAs and Long Non-Coding RNAs in Cancer Prevention and Therapy. Phyther. Res. 2022, 36, 705–729. [Google Scholar] [CrossRef] [PubMed]
- Park, H.A.; Brown, S.R.; Kim, Y. Cellular Mechanisms of Circulating Tumor Cells during Breast Cancer Metastasis. Int. J. Mol. Sci. 2020, 21, 5040. [Google Scholar] [CrossRef] [PubMed]
- Al-Khalaf, H.H.; Aboussekhra, A. P16INK4A Induces Senescence and Inhibits EMT through MicroRNA-141/MicroRNA-146b-5p-Dependent Repression of AUF1. Mol. Carcinog. 2017, 56, 985–999. [Google Scholar] [CrossRef]
- Chen, J.; Shin, V.Y.; Siu, M.T.; Ho, J.C.W.; Cheuk, I.; Kwong, A. MiR-199a-5p Confers Tumor-Suppressive Role in Triple-Negative Breast Cancer. BMC Cancer 2016, 16, 887. [Google Scholar] [CrossRef] [Green Version]
- Amirfallah, A.; Knutsdottir, H.; Arason, A.; Hilmarsdottir, B.; Johannsson, O.T.; Agnarsson, B.A.; Barkardottir, R.B.; Reynisdottir, I. Hsa-MiR-21-3p Associates with Breast Cancer Patient Survival and Targets Genes in Tumor Suppressive Pathways. PLoS ONE 2021, 16, e0260327. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.; Wang, D.; Ren, H.; Shi, Y.; Gao, Y. MiR-145-Targeted HBXIP Modulates Human Breast Cancer Cell Proliferation. Thorac. Cancer 2019, 10, 71–77. [Google Scholar] [CrossRef] [Green Version]
- Wang, J.; Yan, Y.; Zhang, Z.; Li, Y. Role of MiR-10b-5p in the Prognosis of Breast Cancer. PeerJ 2019, 2019, e7728. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhai, Z.; Mu, T.; Zhao, L.; Li, Y.; Zhu, D.; Pan, Y. MiR-181a-5p Facilitates Proliferation, Invasion, and Glycolysis of Breast Cancer through NDRG2-Mediated Activation of PTEN/AKT Pathway. Bioengineered 2022, 13, 83–95. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Tan, Z.; Hu, H.; Liu, H.; Wu, T.; Zheng, C.; Wang, X.; Luo, Z.; Wang, J.; Liu, S.; et al. MicroRNA-21 Promotes Breast Cancer Proliferation and Metastasis by Targeting LZTFL1. BMC Cancer 2019, 19, 738. [Google Scholar] [CrossRef] [Green Version]
- Yu, J.; Shen, W.; Gao, B.; Zhao, H.; Xu, J.; Gong, B. MicroRNA-182 Targets FOXF2 to Promote the Development of Triple-Negative Breast Cancer. Neoplasma 2017, 64, 209–215. [Google Scholar] [CrossRef] [Green Version]
- Huang, R.; Li, J.; Pan, F.; Zhang, B.; Yao, Y. The Activation of GPER Inhibits Cells Proliferation, Invasion and EMT of Triple-Negative Breast Cancer via CD151/MiR-199a-3p Bio-Axis. Am. J. Transl. Res. 2020, 12, 32–44. [Google Scholar] [PubMed]
- Shen, Y.; Xu, Y.; Huang, L.; Chi, Y.; Meng, L. MiR-205 Suppressed the Malignant Behaviors of Breast Cancer Cells by Targeting CLDN11 via Modulation of the Epithelial-to-Mesenchymal Transition. Aging 2021, 13, 13073–13085. [Google Scholar] [CrossRef]
- Fu, H.; Fu, L.; Xie, C.; Zuo, W.S.; Liu, Y.S.; Zheng, M.Z.; Yu, J.M. CancermiR-375 Inhibits Cancer Stem Cell Phenotype and Tamoxifen Resistance by Degrading HOXB3 in Human ER-Positive Breast Cancer. Oncol. Rep. 2017, 37, 1093–1099. [Google Scholar] [CrossRef] [Green Version]
- Purohit, P.K.; Edwards, R.; Tokatlidis, K.; Saini, N. MiR-195 Regulates Mitochondrial Function by Targeting Mitofusin-2 in Breast Cancer Cells. RNA Biol. 2019, 16, 918–929. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, X.; Zhang, Y.; Jasper, J.; Lykken, E.; Alexander, P.B.; Markowitz, G.J.; McDonnell, D.P.; Li, Q.J.; Wang, X.F. MiR-148a Functions to Suppress Metastasis and Serves as a Prognostic Indicator in Triple-Negative Breast Cancer. Oncotarget 2016, 7, 20381–20394. [Google Scholar] [CrossRef] [Green Version]
- Xu, Q.; Liu, L.-Z.; Yin, Y.; He, J.; Li, Q.; Qian, X.; You, Y.; Lu, Z.; Peiper, S.C.; Shu, Y.; et al. Regulatory Circuit of PKM2/NF-ΚB/MiR-148a/152-Modulated Tumor Angiogenesis and Cancer Progression. Oncogene 2015, 34, 5482–5493. [Google Scholar] [CrossRef] [PubMed]
- Furrer, D.; Paquet, C.; Jacob, S.; Diorio, C. The Human Epidermal Growth Factor Receptor 2 (HER2) as a Prognostic and Predictive Biomarker: Molecular Insights into HER2 Activation and Diagnostic Implications. In Cancer Prognosis; Lemamy, G.-J., Ed.; IntechOpen: Rijeka, Croatia, 2018. [Google Scholar]
- Zhang, S.; Wang, Y.; Wang, Y.; Peng, J.; Yuan, C.; Zhou, L.; Xu, S.; Lin, Y.; Du, Y.; Yang, F.; et al. Serum MiR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy. Front. Oncol. 2020, 10, 631. [Google Scholar] [CrossRef]
- Shen, H.; Wang, D.; Li, L.; Yang, S.; Chen, X.; Zhou, S.; Zhong, S.; Zhao, J.; Tang, J. MiR-222 Promotes Drug-Resistance of Breast Cancer Cells to Adriamycin via Modulation of PTEN/Akt/FOXO1 Pathway. Gene 2017, 596, 110–118. [Google Scholar] [CrossRef]
- Zhong, W.; Chen, S.; Qin, Y.; Zhang, H.; Wang, H.; Meng, J.; Huai, L.; Zhang, Q.; Yin, T.; Lei, Y.; et al. Doxycycline Inhibits Breast Cancer EMT and Metastasis through PAR-1/NF-ΚB/MiR-17/E-Cadherin Pathway. Oncotarget 2017, 8, 104855–104866. [Google Scholar] [CrossRef] [Green Version]
- Zhao, L.; Zhao, Y.; He, Y.; Mao, Y. MiR-19b Promotes Breast Cancer Metastasis through Targeting MYLIP and Its Related Cell Adhesion Molecules. Oncotarget 2017, 8, 64330–64343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yin, H.; Wang, Y.; Wu, Y.; Zhang, X.; Zhang, X.; Liu, J.; Wang, T.; Fan, J.; Sun, J.; Yang, A.; et al. EZH2-Mediated Epigenetic Silencing of MiR-29/MiR-30 Targets LOXL4 and Contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. Theranostics 2020, 10, 8494–8512. [Google Scholar] [CrossRef]
- Xing, Z.; Wang, X.; Liu, J.; Liu, G.; Zhang, M.; Feng, K.; Wang, X. Effect of MiR-210 on the Chemosensitivity of Breast Cancer by Regulating JAK-STAT Signaling Pathway. Biomed Res. Int. 2021, 2021, 7703159. [Google Scholar] [CrossRef] [PubMed]
- Hong, L.; Yang, J.; Han, Y.; Lu, Q.; Cao, J.; Syed, L. High Expression of MiR-210 Predicts Poor Survival in Patients with Breast Cancer: A Meta-Analysis. Gene 2012, 507, 135–138. [Google Scholar] [CrossRef]
- Kim, J.-Y.; Jung, E.J.; Kim, J.-M.; Son, Y.; Lee, H.S.; Kwag, S.-J.; Park, J.-H.; Cho, J.-K.; Kim, H.-G.; Park, T.; et al. MiR-221 and MiR-222 Regulate Cell Cycle Progression and Affect Chemosensitivity in Breast Cancer by Targeting ANXA3. Exp. Ther. Med. 2023, 25, 11826. [Google Scholar] [CrossRef]
- Moorthy, R.K.; Srinivasan, C.; Kannan, M.; Arockiam, A.J.V. Deregulation of MiR-375 Inhibits HOXA5 and Promotes Migration, Invasion, and Cell Proliferation in Breast Cancer. Appl. Biochem. Biotechnol. 2023. [Google Scholar] [CrossRef]
- Cui, F.; Zhou, Q.; Xiao, K.; Ma, S. The MicroRNA Hsa-Let-7g Promotes Proliferation and Inhibits Apoptosis in Lung Cancer by Targeting HOXB1. Yonsei Med. J. 2020, 61, 210–217. [Google Scholar] [CrossRef]
- Najjary, S.; Mohammadzadeh, R.; Mokhtarzadeh, A.; Mohammadi, A.; Kojabad, A.B.; Baradaran, B. Role of MiR-21 as an Authentic Oncogene in Mediating Drug Resistance in Breast Cancer. Gene 2020, 738, 144453. [Google Scholar] [CrossRef]
- Yin, Y.; Wang, X.; Li, T.; Ren, Q.; Li, L.; Sun, X.; Zhang, B.; Wang, X.; Han, H.; He, Y.; et al. MicroRNA-221 Promotes Breast Cancer Resistance to Adriamycin via Modulation of PTEN/Akt/MTOR Signaling. Cancer Med. 2020, 9, 1544–1552. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Si, C.; Yu, Q.; Yao, Y. Effect of MiR-146a-5p on Proliferation and Metastasis of Triple-Negative Breast Cancer via Regulation of SOX5. Exp. Ther. Med. 2018, 15, 4515–4521. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tormo, E.; Adam-Artigues, A.; Ballester, S.; Pineda, B.; Zazo, S.; González-Alonso, P.; Albanell, J.; Rovira, A.; Rojo, F.; Lluch, A.; et al. The Role of MiR-26a and MiR-30b in HER2+ Breast Cancer Trastuzumab Resistance and Regulation of the CCNE2 Gene. Sci. Rep. 2017, 7, srep41309. [Google Scholar] [CrossRef] [Green Version]
- Wu, T.; Song, H.; Xie, D.; Hua, K.; Hu, J.; Deng, Y.; Ji, C.; Fang, L. Mir-30b-5p Promotes Proliferation, Migration, and Invasion of Breast Cancer Cells via Targeting ASPP2. Biomed Res. Int. 2020, 2020, 7907269. [Google Scholar] [CrossRef] [PubMed]
- Liu, T.; Ye, P.; Ye, Y.; Lu, S.; Han, B. Circular RNA Hsa_circRNA_002178 Silencing Retards Breast Cancer Progression via MicroRNA-328-3p-Mediated Inhibition of COL1A1. J. Cell. Mol. Med. 2020, 24, 2189–2201. [Google Scholar] [CrossRef]
- Jiang, Y.; Wang, B.; Li, J.K.; Li, S.Y.; Niu, R.L.; Fu, N.Q.; Zheng, J.J.; Liu, G.; Wang, Z.L. Collagen Fiber Features and COL1A1: Are They Associated with Elastic Parameters in Breast Lesions, and Can COL1A1 Predict Axillary Lymph Node Metastasis? BMC Cancer 2022, 22, 1004. [Google Scholar] [CrossRef]
- Dai, T.; Zhao, X.; Li, Y.; Yu, L.; Li, Y.; Zhou, X.; Gong, Q. Mir-423 Promotes Breast Cancer Invasion by Activating Nf-Κb Signaling. Onco. Targets. Ther. 2020, 13, 5467–5478. [Google Scholar] [CrossRef]
- Umeh-Garcia, M.; Simion, C.; Ho, P.Y.; Batra, N.; Berg, A.L.; Carraway, K.L.; Yu, A.; Sweeney, C. A Novel Bioengineered MiR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells. Cancer Res. 2020, 80, 418–429. [Google Scholar] [CrossRef] [Green Version]
- Wen, X.; Dai, Y.; Wu, S.; Li, J. MiR-127-3p Inhibits Breast Cancer Cell Behaviors via Targeting Benzodiazepine Receptor-Associated Protein 1 (BZRAP1). J. Biomater. Tissue Eng. 2022, 12, 2038–2043. [Google Scholar] [CrossRef]
- Song, W.; Wu, S.; Wu, Q.; Zhou, L.; Yu, L.; Zhu, B.; Gong, X. The MicroRNA-141-3p/ CDK8 Pathway Regulates the Chemosensitivity of Breast Cancer Cells to Trastuzumab. J. Cell. Biochem. 2019, 120, 14095–14106. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.; Duan, Z.; Zhang, C.; Wang, W.; He, H.; Liu, Y.; Wu, P.; Wang, S.; Song, M.; Chen, H.; et al. Mouse 4T1 Breast Cancer Cell–Derived Exosomes Induce Proinflammatory Cytokine Production in Macrophages via MiR-183. J. Immunol. 2020, 205, 2916–2925. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Chen, Z.; Fang, M.; Qiao, Y. MicroRNA Let-7a Inhibits Proliferation of Breast Cancer Cell by Downregulating USP32 Expression. Transl. Cancer Res. 2019, 8, 1763–1771. [Google Scholar] [CrossRef]
- Jordan-Alejandre, E.; Campos-Parra, A.D.; Castro-López, D.L.; Silva-Cázares, M.B. Potential MiRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis. Cells 2023, 12, 525. [Google Scholar] [CrossRef]
- Grimaldi, A.M.; Salvatore, M.; Incoronato, M. MiRNA-Based Therapeutics in Breast Cancer: A Systematic Review. Front. Oncol. 2021, 11, 668464. [Google Scholar] [CrossRef]
- Saiyed, A.N.; Vasavada, A.R.; Johar, S.R.K. Recent Trends in MiRNA Therapeutics and the Application of Plant MiRNA for Prevention and Treatment of Human Diseases. Futur. J. Pharm. Sci. 2022, 8, 24. [Google Scholar] [CrossRef]
- Bayraktar, E.; Bayraktar, R.; Oztatlici, H.; Lopez-Berestein, G.; Amero, P.; Rodriguez-Aguayo, C. Targeting MiRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update. Non-Coding RNA 2023, 9, 27. [Google Scholar] [CrossRef] [PubMed]
- Iacomino, G. MiRNAs: The Road from Bench to Bedside. Genes 2023, 14, 314. [Google Scholar] [CrossRef]
- Diener, C.; Keller, A.; Meese, E. Emerging Concepts of MiRNA Therapeutics: From Cells to Clinic. Trends Genet. 2022, 38, 613–626. [Google Scholar] [CrossRef]
- Samad, A.F.A.; Kamaroddin, M.F. Innovative Approaches in Transforming MicroRNAs into Therapeutic Tools. WIREs RNA 2023, 14, e1768. [Google Scholar] [CrossRef] [PubMed]
Associated miRNAs | Target mRNA | Altered Biological Mechanism | Source | Reference |
---|---|---|---|---|
miR-222 ↑ | TRPS1 Notch3 | EMT | Plasma | [52] |
miR-20a ↑ | ZBTB4 | Cell growth and invasion | ||
miR-451 ↓ | MRP-1 | Anthracycline resistance | ||
miR-34a ↓ | Bcl-2 SIRT1 | Apoptosis | ||
miR-155 ↓ | ErbB2 HDAC2 | Cell survival, growth, and chemosensitivity | Plasma | [53] |
miR-301 ↓ | ESR1 | Cell growth and invasion | ||
miR-146b-5p ↓ | ZEB1 | EMT | Plasma | [54] |
miR-199a-5p ↑ | CDH1, ZEB1, TWIST | |||
miR-148a-3p ↑ | PKM2 | Malignant phenotype maintenance | Plasma | [55] |
miR-374a-5p ↑ | ARRB1 | Cell survival, proliferation, and migration | [55,56] | |
miR-21-5p ↓ | PTEN PDCD4 | Chemoresistance | Plasma | [57] |
miR-221-3p ↓ | PTEN | |||
miR-146a-5p ↓ | SOX5 | EMT | ||
miR-26a-5p ↓ | CCNE2 | Chemoresistance | ||
miR-21 ↓ | PTEN | Apoptosis and cell proliferation | Serum | [58] |
miR-21 ↑ | LZTFL1 | Cell proliferation, invasion, and migration | Whole blood | [59] |
miR-195 ↓ | MFN2 | Mitochondrial metabolism | [60] | |
miR-210 ↑ | PIAS4 | Apoptosis, anthracycline resistance | Serum | [14] |
miR-222 ↓ | ANXA3 | Cell proliferation, invasion, and migration | ||
miR-375 ↑ | HOXA5 | Apoptosis, cell proliferation, invasion, and migration | ||
let-7g ↓ | FOXC2 | Cell migration | ||
miR-21-3p ↑ | MAT2 STARD13 ZNF132 | Cell proliferation, invasion, and migration | Serum | [61] |
miR-145-5p ↑ | SOX2 | Cell proliferation | ||
miR-145 ↑ | HBXIP | |||
miR-10b-5 ↑ | BIRC5 E2F2 KIF2C FOXM1 MCM5 | |||
miR-181a ↑ | SOCS3 PIAS3 ATM | Cell proliferation, invasion, and migration | Whole blood | [62] |
miR-181a-5p ↑ | NDRG2 | |||
miR-105 ↑ | ZO-1 | |||
miR-221 ↑ | ERα | |||
miR-222 ↑ | ERα | |||
miR-155 ↑ | PTEN | |||
miR-30b-5p ↑ | ASPP2 | Apoptosis and EMT | Plasma | [63] |
miR-328-3p ↑ | COL1A1 | Inflammation | ||
miR-423-5p ↑ | TNIP2 | Cell invasion | ||
miR-127-3p ↑ | CERK NANOS1 FOXO6 SOX11 SOX12 FASN SUSD2 BZRAP1 | Cell proliferation, invasion, and migration | ||
miR-141-3p ↑ | CDK8 | Chemoresistance | ||
miR-34a-5p ↑ | B7-H1 | Apoptosis, cell proliferation, invasion, and migration | ||
miR-183-5p ↑ | PPP2CA | Cell proliferation, invasion, and migration | ||
miR-182-5p ↑ | CMTM7 | Cell proliferation, invasion, and migration | ||
miR-376c-3p ↓ | RAB2A | Malignant phenotype maintenance Cell stemness | Plasma | [56] |
miR-197-3p ↓ | HIPK3 | Apoptosis, cell proliferation, invasion, and migration | ||
miR-874-3p ↑ | SOX2 | Tumor growth | ||
miR-320c ↑ | AQP1 | Cell proliferation | ||
miR-100-5p ↑ | PlK1 | Cell proliferation, invasion, and migration | ||
miR-144-3p ↑ | SOX2 | Tumor growth Cell stemness | ||
miR-362-3p ↑ | hERG | Apoptosis, cell proliferation, invasion, and migration | ||
miR-374a-5p ↑ | ARRB1 | Tumor progression | ||
miR-574-3p ↑ | ADAM28 | Tumor progression | ||
miR-140-5p ↑ | Wnt1 | Cell proliferation, invasion, and migration | ||
miR-145-5p ↑ | SOX2 | Tumor growth Cell stemness | ||
miR-328-3p ↓ | Ki-67 | Cell proliferation | ||
miR-34a-5p ↓ | PD-L1 P53 | Apoptosis, cell proliferation, invasion, and migration | ||
miR-98-5p ↑ | IGF1 | Cell proliferation, invasion, and migration | ||
miR-182 ↑ | FOXF2 | Cell proliferation and migration | Serum | [64] |
miR-375 ↓ | HOXB3 | Malignant phenotype maintenance Cell stemness Chemoresistance | ||
miR-205 ↑ | CLDN11 | Apoptosis and cell proliferation | ||
miR-21 ↓ | LZTFL1 | EMT | ||
miR-199a ↓ | CD151 | Cell proliferation, invasion, and migration Angiogenesis | ||
miR-155 ↑ | SOCS1 MMP16 | Cell proliferation and migration | ||
miR-17 ↓ | E-cadherin | EMT | Serum | [65] |
miR-19b ↓ | MYLIP E-cadherin ICAM-1 Inregrin β1 | Cell adhesion | ||
miR-30 ↓ | LOXL4 | Cell proliferation, invasion, and migration | ||
let-7a ↑ | USP32 | Cell proliferation | Whole blood | [66] |
miR-21 ↑ | LZTFL1 | Cell proliferation, invasion, and migration | ||
miR-145 ↓ | SOX2 | Tumor growth Cell stemness |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ruiz-Manriquez, L.M.; Villarreal-Garza, C.; Benavides-Aguilar, J.A.; Torres-Copado, A.; Isidoro-Sánchez, J.; Estrada-Meza, C.; Arvizu-Espinosa, M.G.; Paul, S.; Cuevas-Diaz Duran, R. Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer. Int. J. Mol. Sci. 2023, 24, 9984. https://doi.org/10.3390/ijms24129984
Ruiz-Manriquez LM, Villarreal-Garza C, Benavides-Aguilar JA, Torres-Copado A, Isidoro-Sánchez J, Estrada-Meza C, Arvizu-Espinosa MG, Paul S, Cuevas-Diaz Duran R. Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer. International Journal of Molecular Sciences. 2023; 24(12):9984. https://doi.org/10.3390/ijms24129984
Chicago/Turabian StyleRuiz-Manriquez, Luis M., Cynthia Villarreal-Garza, Javier A. Benavides-Aguilar, Andrea Torres-Copado, José Isidoro-Sánchez, Carolina Estrada-Meza, María Goretti Arvizu-Espinosa, Sujay Paul, and Raquel Cuevas-Diaz Duran. 2023. "Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer" International Journal of Molecular Sciences 24, no. 12: 9984. https://doi.org/10.3390/ijms24129984